S. 932In Committee
Give Kids a Chance Act of 2025
Authorizes combination drug trials for pediatric cancer and renews the FDA rare pediatric disease priority review voucher program through September 30, 2029
Plain-English overview
What this bill does
Authorizes combination drug trials for pediatric cancer and renews the FDA rare pediatric disease priority review voucher program through September 30, 2029
Key points
- Require FDA and GAO reports
- Authorize pediatric cancer combination trials
- Modify targeted investigation requirements
- Extend rare pediatric disease vouchers
Current status
Where it stands
Status
In Committee
Latest action
2025-03-11 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related context
Topics and policy areas
undefinedHealth